AstraZeneca PLC
AZN
AstraZeneca PLC is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. AstraZeneca PLC focuses on major therapeutic areas including oncology, rare diseases, cardiovascular, renal and metabolism, respiratory and immunology, and vaccines and immune therapies. Its portfolio includes treatments used in cancer care, chronic disease management, respiratory conditions, and specialty medicines for rare and complex disorders. The company serves healthcare providers, hospitals, and patients in markets around the world, with a business model centered on research-driven drug development and broad commercial distribution. Headquartered in Cambridge, United Kingdom, AstraZeneca PLC plays a significant role in the global pharmaceutical market through its branded medicines portfolio and ongoing clinical development programs.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$61.37B
▲ +47.9% YoY
Net Income (TTM)
$10.45B
▲ +97.8% YoY
Op. Margin
22.77%
▲ +3.7pp YoY
ROIC
16.92%
▲ +6.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$6.04B
▲ +62.2% YoY
Op. Cash Flow (TTM)
$13.70B
▲ +134.4% YoY
Net Debt
$23.43B
Cash & Equiv.
$5.72B
3Y CAGR: +9.8%
3Y CAGR: +6.2%
Continue Research
Held by ETFs
AZN.XLON is in 202 US ETFs. The largest of them, with AZN.XLON's weight in each:
Vanguard Total International Stock ETFVXUS0.54%of the fund
iShares Core MSCI EAFE ETFIEFA1.03%of the fund
AstraZeneca (AZN.XLON) in four numbers
Questions about AstraZeneca
Is AstraZeneca (AZN.XLON) overvalued?
At £138.85, AstraZeneca's price is 44% below the £246.51 a share fair value that Intrinsiqq's calculator gets from its earnings. It trades at 27.59 times earnings and 47.69 times free cash flow. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is AstraZeneca's fair value?
Intrinsiqq's calculator puts AstraZeneca's fair value at £246.51 a share. It grows earnings per share 20% a year for 5 years, applies an exit P/E of 29.7, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of £184.89. Every input can be changed on the Intrinsic Value tab.
Is AstraZeneca a high-quality business?
AstraZeneca scores 56 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 8 checks computed from company filings. Its best check is margin trend at +12.6pp, and its weakest is net debt at $23.43B. The Quality tab shows every check against its target.
Does AstraZeneca (AZN.XLON) pay a dividend, and how much?
Yes. AstraZeneca (AZN.XLON) pays a dividend: $3.17 per share over the last twelve months, a dividend yield of 1.72% at the latest close. It has raised its dividend per share for 2 years in a row, growing at 2.1% a year over the last 5 years. The payout takes about 47.4% of earnings.
Source: company filings. Price: last close 11 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing AZN
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.